Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.50 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414991 | 0.90 | GRM5 (0.52) | GRM5TACR2TACR1KITNPC1 | |
| SCHEMBL3416183 | 0.86 | GRM5 (0.50) | GRM5NPC1PTGDR2 | |
| SCHEMBL3416230 | 0.85 | GRM5 (0.48) | GRM5TACR3KIT | |
| SCHEMBL3412333 | 0.84 | GRM5 (0.54) | GRM5TACR2TACR1KITNPC1 | |
| SCHEMBL3415277 | 0.84 | GRM5 (0.58) | GRM5NPC1 | |
| SCHEMBL3412941 | 0.83 | GRM5 (0.53) | GRM5TACR2TACR1KITNPC1 | |
| SCHEMBL3412248 | 0.82 | GRM5 (0.48) | GRM5TACR3KIT | |
| SCHEMBL3414971 | 0.82 | GRM5 (0.48) | GRM5TACR3KIT | |
| SCHEMBL3411248 | 0.81 | GRM5 (0.50) | GRM5TACR3KITPTGDR2 | |
| SCHEMBL3414613 | 0.81 | GRM5 (0.69) | GRM5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | claimed |
| WO-2010124047-A1 | BISARYL ALKYNYLAMIDES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | GRM5, GRM1, GRM2 | GRM5 1/4885TACR3 745/4885TACR2 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.